View Author
dai: 072091967
scopus: 35301012000
Verweij, J.
(Jaap Verweij)Supervisor (promotor) of 23 dissertations
patient cancer study treatment pharmacokinetic phase tumor irinotecan plasma grade toxicity level sarcoma response trial docetaxel group concentration imatinib activity effect analysis oncol tissue paclitaxel cycle disease agent inhibitor table therapy result infusion chemotherapy clearance administration combination sample sn -38 lesion factor -38 survival verweij research oncology progression number value exposure model blood cyp 3a ifosfamide range dosing metabolite tumour metastatic cpt -11 expression tissue sarcomas growth transporter target function phase i study dose level course death cisplatin doxorubicin parameter neutropenia kinase breast -11 stromal stromal tumors pharmacol
10 Most Recent Publications
|
Modifying phase i methodology to facilitate enrolment of molecularly selected patients
(Article)
Hollebecque, A. Postel-Vinay, S. Verweij, J. Demetri, G.D. Flaherty, K.T. Bedard, P. Soria, J.C. |
2013-05-01
|
|
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors
(Article)
Oudijk, L. Gaal, J. Loon, R.L.E. van O'Sullivan, M.J. Krijger, R.R. de Dinjens, W.N.M. Korpershoek, E. Nederveen, F.H. van Kelly, L. Schiavon, G. Verweij, J. Mathijssen, R.H.J. Bakker, M.A. den Oldenburg, R. |
2013-03-01
|
|
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
(Article)
Cesne, A. le Blay, J-Y. Grosso, F. Lardelli, P. Nieto, A. Alfaro, V. Verweij, J. Poveda, A. Casali, P.G. Demetri, G.D. Cresta, S. Maki, R.G. Balaña, C. Schöffski, P. |
2012-06-29
|
|
Reply to F.L. Opdam et al
(Article)
Graan, A-J.M. de Binkhorst, L. Loos, W.J. Schaik, R.H.N. van Verweij, J. Mathijssen, R.H.J. |
2012-02-01
|
|
Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
(Article)
Bendell, J.C. Rodon, J. Goldbrunner, M. Baselga, J. Burris, H.A. Jonge, M.J.A. de Verweij, J. Birle, D. Demanse, D. Buck, S.S. de Ru, Q.C. Peters, M. |
2012-01-20
|
|
Erlotinib dosing-to-rash: A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
(Article)
Mita, A. Papadopoulos, K. Hamilton, M. Iwata, K.K. Wacker, B. Witte, K. de Rowinsky, E.K. Jonge, M.J.A. de Schwartz, G. Verweij, J. Ricart, A. Chu, Q.S.C. Tolcher, A.W. Wood, L. McCarthy, S.W. |
2011-09-27
|
|
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
(Article)
Graan, A-J.M. de Teunissen, S.F. Beijnen, J.H. Mathijssen, R.H.J. Vos, F.Y.F.L. de Loos, W.J. Schaik, R.H.N. van Jongh, F.E. de Alphen, R.J. van Holt, B. van der Verweij, J. Seynaeve, C.M. |
2011-08-20
|
|
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
(Article)
Hamberg, P. Woo, M.M. Jonge, M.J.A. de Chen, L.C. Verweij, J. Porro, M.G. Zhao, L. Li, W. Biessen, D. van der Sharma, H.S. Hengelage, T. |
2011-06-27
|
|
Phase i safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
(Article)
Jonge, M.J.A. de Dumez, H. Kitzen, J.J.E.M. Beuselinck, B. Verweij, J. Courtney, R. Battista, A. Brega, N. Schöffski, P. |
2011-06-01
|
|
Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2
(Article)
Eechoute, K. Franke, R.M. Sparreboom, A. Loos, W.J. Scherkenbach, L.A. Boer, I.H. de Verweij, J. Gurney, H. Kim, R.B. Tirona, R.G. Mathijssen, R.H.J. |
2011-04-20
|
